DK2576790T3 - Vitronectin:keratinocytvækstfaktor-kimærer - Google Patents

Vitronectin:keratinocytvækstfaktor-kimærer Download PDF

Info

Publication number
DK2576790T3
DK2576790T3 DK11788988.1T DK11788988T DK2576790T3 DK 2576790 T3 DK2576790 T3 DK 2576790T3 DK 11788988 T DK11788988 T DK 11788988T DK 2576790 T3 DK2576790 T3 DK 2576790T3
Authority
DK
Denmark
Prior art keywords
seq
protein complex
isolated protein
integrin
sequence
Prior art date
Application number
DK11788988.1T
Other languages
English (en)
Inventor
Zee Upton
Original Assignee
Tissue Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissue Therapies Ltd filed Critical Tissue Therapies Ltd
Application granted granted Critical
Publication of DK2576790T3 publication Critical patent/DK2576790T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (17)

1. Isoleret proteinkompleks i form af et syntetisk kimært protein, der omfatter en aminosyresekvens for: (i) keratinocytvækstfaktor (KGF) eller mindst et domæne af KGF, som er i stand til at binde til en keratinocytvækstfaktorreceptor; og (ii) et eller flere domæner af vitronectin (VN), som omfatter mindst et integrinbindende domæne af VN.
2. Isoleret proteinkompleks ifølge krav 1, hvor det ene eller de flere domæner af VN, der omfatter mindst et integrinbindende domæne af VN, ikke inkluderer et C-terminalt heparinbindende domæne (HBD).
3. Isoleret proteinkompleks ifølge krav 2, der omfatter aminosyrerne 1-346 af en moden VN-sekvens som vist i SEQ ID NO: 2 .
4. Isoleret proteinkompleks ifølge et hvilket som helst af kravene 1-3, hvor det integrinbindende domæne er et cxv- integrinbindende domæne, såsom et oo^3-integrinbindende domæne eller et oo^s-integrinbindende domæne.
5. Isoleret proteinkompleks ifølge krav 1, hvor det ene eller de flere domæner af VN, der omfatter mindst et integrinbindende domæne af VN, omfatter aminosyrerne 1-311 af en moden VN-sekvens som vist i SEQ ID NO: 2; eller aminosyrerne 1-125 af en moden VN-sekvens som vist i SEQ ID NO: 2; eller aminosyrerne 1-64 af en moden VN-sekvens som vist i SEQ ID NO: 2; eller aminosyrerne 1-52 af en moden VN-sekvens som vist i SEQ ID NO: 2.
6. Isoleret proteinkompleks ifølge krav 5, hvor det ene eller de flere domæner af VN, der omfatter mindst et integrinbindende domæne af VN, ikke omfatter en polyanionisk aminosyresekvens, der svarer til resterne 53-64 af et modent VN-protein som vist i SEQ ID NO: 2.
7. Isoleret proteinkompleks ifølge et hvilket som helst af ovennævnte krav, der yderligere omfatter et ekstra fragment af VN.
8. Isoleret proteinkompleks ifølge et hvilket som helst af ovennævnte krav, der yderligere omfatter mindst én linkersekvens, som eventuelt kan omfatte et proteasespaltningssted og eventuelt er udvalgt fra gruppen, der består af: (i) Gly4Ser (SEQ ID NO: 4); (ii) Gly4Ser3 (SEQ ID NO: 5) ; (iii) (Gly4Ser)3 (SEQ ID NO: 6); (iv) (Gly4Ser)4 (SEQ ID NO: 7); (v) Leu Ile Lys Met Lys Pro (SEQ ID NO: 8); og (vi) Gin Pro Gin Gly Leu Ala Lys (SEQ ID NO: 9).
9. Isoleret proteinkompleks ifølge krav 1, hvor det syntetiske kimære protein omfatter en aminosyresekvens: VNi_459 : (Gly4Ser) 4: KGFi_i63 : Gly4SerGly4His6 som vist i SEQ ID NO: 10; VNi-3h : (Gly4Ser) 4: KGFi_i63 : Gly4SerGly4His6 som vist i SEQ ID NO: 11; VNi-125 : (Gly4Ser) 4: KGFi_i63 : Gly4SerGly4His6 som vist i SEQ ID NO: 12; VNi_64 : (Gly4Ser) 4: KGFi_i63 : Gly4SerGly4His6 som vist i SEQ ID NO: 13; VNi-i64: (Gly4Ser) 4: VN343-376 : (Gly4Ser) 4: KGFi_i63 : Gly4SerGly4His6 som vist i SEQ ID NO: 14 .
10. Isoleret nukleinsyre, der koder for det isolerede proteinkompleks ifølge et hvilket som helst af ovennævnte krav.
11. Genkonstruktion, der omfatter den isolerede nukleinsyre ifølge krav 10, der er operabelt koblet til en eller flere regulatoriske nukleotidsekvenser i en vektor, hvor den regulatoriske nukleotidsekvens kan være en promotor.
12. Værtscelle, der omfatter genkonstruktionen ifølge krav 11.
13. Farmaceutisk sammensætning, der omfatter det isolerede proteinkompleks ifølge et hvilket som helst af kravene 1-9 og et farmaceutisk acceptabelt bæremateriale, fortyndingsmiddel eller excipiens.
14. Sår- eller forbrændingsbandage, kirurgisk implantat, gittersystem eller protese, der er imprægneret med, beklædt med eller på anden vis omfatter det isolerede proteinkompleks ifølge et hvilket som helst af kravene 1-9.
15. Isoleret proteinkompleks ifølge et hvilket som helst af kravene 1-9 til anvendelse til fremme af cellemigration og/eller proliferation, hvor komplekset binder til både en keratinocytvækstfaktorreceptor og en integrinreceptor, der udtrykkes af en celle, til derved inducering, forøgelse eller på anden vis fremme af migration og/eller proliferation af cellen.
16. Isoleret proteinkompleks ifølge et hvilket som helst af kravene 1-9 til anvendelse til fremme af sårheling in situ hos et dyr, hvor det isolerede proteinkompleks administreres til et dyr, såsom et menneske, til binding til både en keratinocytvækstfaktorreceptor og en integrinreceptor, der udtrykkes af en celle, til derved fremme af cellemigration og/eller proliferation in situ, for eksempel til profylaktisk eller terapeutisk inducering, forøgelse eller på anden vis fremme af epitelcellemigration og/eller proliferation.
17. Isoleret proteinkompleks til anvendelse ifølge krav 16, hvor det isolerede proteinkompleks administreres til en eller flere celler eller væv in vitro.
DK11788988.1T 2010-06-03 2011-06-03 Vitronectin:keratinocytvækstfaktor-kimærer DK2576790T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/793,386 US8871709B2 (en) 2003-02-05 2010-06-03 Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
PCT/AU2011/000700 WO2011150470A1 (en) 2010-06-03 2011-06-03 Vitronectin:keratinocyte growth factor chimeras

Publications (1)

Publication Number Publication Date
DK2576790T3 true DK2576790T3 (da) 2016-04-11

Family

ID=45066067

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11788988.1T DK2576790T3 (da) 2010-06-03 2011-06-03 Vitronectin:keratinocytvækstfaktor-kimærer

Country Status (12)

Country Link
US (2) US8871709B2 (da)
EP (1) EP2576790B1 (da)
JP (1) JP5843175B2 (da)
KR (1) KR20130115994A (da)
CN (2) CN103038351A (da)
AU (1) AU2011261177B2 (da)
BR (1) BR112012030821A2 (da)
CA (1) CA2801240A1 (da)
DK (1) DK2576790T3 (da)
NZ (1) NZ603942A (da)
RU (1) RU2012156861A (da)
WO (1) WO2011150470A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871709B2 (en) 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
WO2014078896A1 (en) * 2012-11-22 2014-05-30 Queensland University Of Technology Complex-formation-modulating agents and uses therefor
WO2015004148A1 (en) * 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
WO2019010533A1 (en) * 2017-07-12 2019-01-17 Factor Therapeutics Limited TREATMENT OF OCULAR DISORDERS
WO2020051223A1 (en) 2018-09-04 2020-03-12 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
EP3846857A4 (en) 2018-09-04 2022-10-12 The Board Of Regents Of The University Of Texas System COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234071A (zh) * 1996-08-13 1999-11-03 人类基因组科学公司 角质形成细胞生长因子－2(kgf－2或成纤维细胞生长因子－12,fgf－12)
AUPP298498A0 (en) * 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
AU3897200A (en) 1999-03-18 2000-10-04 Hope Heart Institute, The Endothelial cell stimulation by a complex of fibronectin and vascular endothelial growth factor
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US8871709B2 (en) 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
WO2008157483A2 (en) * 2007-06-14 2008-12-24 The Research Foundation Of State University Of New York Polypeptides and methods of use
AU2008295441A1 (en) * 2007-09-04 2009-03-12 Queensland University Of Technology A feeder cell-free culture medium and system
CN102725308A (zh) * 2009-11-30 2012-10-10 昆士兰技术大学 纤连蛋白:生长因子嵌合物

Also Published As

Publication number Publication date
NZ603942A (en) 2014-07-25
US9562086B2 (en) 2017-02-07
BR112012030821A2 (pt) 2019-02-12
EP2576790A4 (en) 2014-03-19
WO2011150470A1 (en) 2011-12-08
US8871709B2 (en) 2014-10-28
RU2012156861A (ru) 2014-07-20
CN103038351A (zh) 2013-04-10
JP2013530161A (ja) 2013-07-25
US20130243843A1 (en) 2013-09-19
KR20130115994A (ko) 2013-10-22
US20100303884A1 (en) 2010-12-02
JP5843175B2 (ja) 2016-01-13
HK1183908A1 (zh) 2014-01-10
CN106243228A (zh) 2016-12-21
EP2576790A1 (en) 2013-04-10
CA2801240A1 (en) 2011-12-08
AU2011261177B2 (en) 2013-09-26
EP2576790B1 (en) 2016-01-06
AU2011261177A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
CA2515335C (en) Growth factor complexes and modulation of cell migration and growth
DK2576790T3 (da) Vitronectin:keratinocytvækstfaktor-kimærer
EP2507261B1 (en) Fibronectin: growth factor chimeras
US9090706B2 (en) Fibronectin: growth factor chimeras
HK1183908B (en) Vitronectin:keratinocyte growth factor chimeras
AU2004208856B2 (en) Growth factor complexes and modulation of cell migration and growth
HK1232554A1 (en) Vitronectin:keratinocyte growth factor chimeras
HK1176360A (en) Fibronectin: growth factor chimeras
HK1176360B (en) Fibronectin: growth factor chimeras
HK1160865A (en) Growth factor complexes and modulation of cell migration and growth
HK1160866A (en) Growth factor complexes and modulation of cell migration and growth